Wife-and-husband team, J. Jean Cui and Y. Peter Li, launched Blossomhill Therapeutics Inc. in mid-2020 to focus on next-generation, macrocyclic inhibitors against oncology targets. The couple had planned to take some time off to rest and do a little traveling, but then the pandemic hit. “This was a great time [to start a new company],” Cui told BioWorld. “Nothing to do but reading and thinking.”
Researchers from Chemdiv Inc. and Eilean Therapeutics LLC recently presented preclinical data on ZE77-0273, an AI-designed, reversible pan-EGFR inhibitor developed to address a key unmet need in the treatment of EGFR-mutant non-small-cell lung cancer.
A Black Diamond Therapeutics Inc. patent describes new alkyne-substituted quinazoline derivatives acting as EGFR (HER1; erbB1) inhibitors particularly, EGFR mutant inhibitors, potentially useful for the treatment of cancer.
Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged prop-2-ynamide derivatives acting as EGFR (Exon 20 insertion [Ex20Ins] mutant) inhibitors reported to be useful for the treatment of cancer, in particular non-small-cell lung cancer (NSCLC).
Acerand Therapeutics (Hong Kong) Ltd. has synthesized compounds acting as EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer.
Unogen Biotech Ltd. has identified triple inhibitors of EGFR (HER1; erbB1), ALK tyrosine kinase receptor and hepatocyte growth factor receptor (HGFR; MET) reported to be useful for the treatment of (non-small-cell) lung cancer.
